Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Kleo Pharmaceuticals, a US-based immunotherapy developer spun out of Yale University, has been acquired by biopharmaceutical company Biohaven.
The all-stock transaction valued Kleo at approximately $20m. Biohaven, also a Yale spinout, already owned a 42% stake in Kleo.
Founded in 2015, Kleo Pharmaceuticals is working on immunotherapies that target cancerous and virally infected cells. It has treatments in development for conditions including multiple myeloma and covid-19.
Kleo emerged out of Prof David Spiegler’s lab and as part…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
